Baijin Life Science Holdings (1466) Announces Strategic Cooperation with Shanghai Guhuan Medical Equipment

Bulletin Express
Dec 01

Baijin Life Science Holdings Limited (Stock Code: 1466) has announced that its indirect wholly-owned subsidiary, Beijing Baijin Biotechnology Company Limited, entered into a strategic cooperation framework agreement with Shanghai Guhuan Medical Equipment Company Limited. The agreement aims to support an equity subscription and establish a sales channel of branded medical products for self-operated stores. It is effective until December 31, 2026, with provision for either party to terminate with 10 days’ notice.

The announcement indicates that Mr. Liang Liang will be proposed as head of the Group’s medical business division, overseeing medical product business expansion. Shanghai Guhuan Medical Equipment Company Limited has more than ten years of experience in medical product supply chains, and Mr. Liang Liang brings extensive background in the medical cosmetic industry. Baijin Life Science Holdings believes this cooperation will help optimize its market ecosystem and expand revenue streams.

The agreement is intended only to reflect preliminary cooperation intentions. Any substantive rights or obligations remain subject to further formal arrangements, which may or may not materialize. Baijin Life Science Holdings will provide additional announcements if necessary. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10